US OptionsDetailed Quotes

AKRO250516P57500

Watchlist

7.20
0.000.00%

15min DelayClose Apr 24 15:59 ET

0.00High0.00Low

Akero Therapeutics Stock Discussion

Teddy123

Feb 28 20:06

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

$Akero Therapeutics (AKRO.US)$
Can Akero's Breakthrough Cirrhosis Reversal Results Reshape MASH Treatment Landscape?

Jaguar8

Jan 27 20:38

NEWS

$Akero Therapeutics (AKRO.US)$
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
Akero Therapeutics (NASDAQ: AKRO) has announced significant topline results from its Phase 2b SYMMETRY study evaluating efruxifermin (EFX) in patients with compensated cirrhosis due to MASH. The study demonstrated statistically significant reversal of c...

Jaguar8

Jan 27 20:37

😍😍😍

$Akero Therapeutics (AKRO.US)$

Jaguar8

Jan 27 05:36

🟠 Watchlist, JANUARY 27,2025, Monday. NFA - DrJag8 (Those who will put other stocks and their picks in comment will be blocked. Make your own list and post instead)

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after ...

Jaguar8

Jan 25 05:27

Take note Monday, January 27, 8AM ET result of SYMMETRY study on MASH cirrhosis

$Akero Therapeutics (AKRO.US)$

Jaguar8

Jan 25 05:26

NEWS

$Akero Therapeutics (AKRO.US)$
Akero To Announce SYMMETRY Study Phase 2b Results For Efruxifermin In MASH Cirrhosis; Investor Webcast Set For Jan. 27 At 8 AM ET
Benzinga
·
About the SYMMETRY Study
The Phase 2b SYMMETRY study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in adult patients with biopsy-confirmed compensated cirrhosis (F4, Child-Pugh A) due to MASH. The study enrolled a total of 182 patients, randomized to receive once-weekly subcutaneous dos...